Therapeutic effects of LDL apheresis in the prevention of atherosclerosis

被引:20
作者
Kajinami, K [1 ]
Mabuchi, H [1 ]
机构
[1] Kanazawa Univ, Sch Med, Dept Internal Med 2, Kanazawa, Ishikawa 9208641, Japan
关键词
D O I
10.1097/00041433-199910000-00004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The efficacy and safety of the therapeutic tool which directly removes LDL particles from circulation (LDL apheresis) has already been established for cholesterol-lowering in patients with refractory hypercholesterolemia, such as homozygous familiar hypercholesterolemia. Several angiographic studies have demonstrated that regular LDL apheresis therapy had favorable effects on the progression of coronary atherosclerosis, Recently, two clinical reports described excellent long-term follow-up results for patients with coronary artery disease who had been treated with LDL apheresis using dextran sulfate cellulose columns plus adjunctive cholesterol-lowering drug therapy. In addition, there is increasing evidence that LDL apheresis is effective for the prevention of extracoronary atherosclerotic disease, and it is also reported to have the potential to improve microvascular disorders. Since the mechanisms of clinical improvement caused by LDL apheresis extend beyond simple and drastic reduction of LDL cholesterol, further investigation based on recent vascular biological evidence is needed. Curr Opin Lipidol 10:401-406. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:401 / 406
页数:6
相关论文
共 37 条
[11]   LDL-apheresis for diabetic nephropathy: A possible new tool [J].
Kobayashi, S .
NEPHRON, 1998, 79 (04) :505-506
[12]  
Koga N, 1997, Ther Apher, V1, P260, DOI 10.1111/j.1744-9987.1997.tb00149.x
[13]   REDUCTION OF LIPOPROTEIN(A) BY LDL-APHERESIS USING A DEXTRAN SULFATE CELLULOSE COLUMN IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA [J].
KOIZUMI, J ;
KOIZUMI, I ;
UNO, Y ;
INAZU, A ;
KAJINAMI, K ;
HARAKI, T ;
YAGI, K ;
KAMON, N ;
MIYAMOTO, S ;
TAKEGOSHI, T ;
MABUCHI, H ;
TAKEDA, R ;
TANI, N ;
TAKADA, S .
ATHEROSCLEROSIS, 1993, 100 (01) :65-74
[14]   LDL-apheresis atherosclerosis regression study (LAARS) - Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis [J].
Kroon, AA ;
Aengevaeren, WRM ;
vanderWerf, T ;
Uijen, GJH ;
Reiber, JHC ;
Bruschke, AVG ;
Stalenhoef, AFH .
CIRCULATION, 1996, 93 (10) :1826-1835
[15]   Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease [J].
Kroon, AA ;
vanAsten, WNJC ;
Stalenhoef, AFH .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (12) :945-+
[16]   EFFECTS OF CS-514 (EPTASTATIN), AN INHIBITOR OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A (HMG-COA) REDUCTASE, ON SERUM-LIPID AND APOLIPOPROTEIN LEVELS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS TREATED BY LOW-DENSITY LIPOPROTEIN (LDL)-APHERESISE [J].
MABUCHI, H ;
FUJITA, H ;
MICHISHITA, I ;
TAKEDA, M ;
KAJINAMI, K ;
KOIZUMI, J ;
TAKEDA, R ;
TAKEGOSHI, T ;
WAKASUGI, T ;
UEDA, K ;
MIYAMOTO, S ;
WATANABE, A ;
OOTA, M .
ATHEROSCLEROSIS, 1988, 72 (2-3) :183-188
[17]   Long-term efficacy of low density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia [J].
Mabuchi, H ;
Koizumi, J ;
Shimizu, M ;
Kajinami, K ;
Miyamoto, S ;
Ueda, K ;
Takegoshi, T .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (12) :1489-1495
[18]  
MABUCHI H, 1990, CURR OPIN LIPIDOL, V1, P43
[19]   Improvement of coronary vasodilatation capacity through single LDL apheresis [J].
Mellwig, KP ;
Baller, D ;
Gleichmann, U ;
Moll, D ;
Betker, S ;
Weise, R ;
Notohamiprodjo, G .
ATHEROSCLEROSIS, 1998, 139 (01) :173-178
[20]   Myocardial perfusion before and after single routine LDL-apheresis [J].
Meyer, C ;
Geiss, HC ;
Duvernoy, CS ;
Parhofer, KG ;
Schwandt, P ;
Schwaiger, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :23A-23A